Clinical trial · Interventional
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
Effectiveness and Safety of Whole-brain Radiotherapy With/Without TMZ Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases: a Multi-institutional, Randomized Controlled Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effects on neurocognitive function of whole-brain radiotherapy (WBRT) with/without TMZ concurrent chemotherapy or avoidance of hippocampus for patients of brain metastases, as well as the feasibility and risk of avoidance of hippocampus during whole-brain radiotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastasis | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Radiation Therapy Complication | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TMZ | Drug | Temozolomide | ALIAS |
| WBRT with avoidance of hippocampus | Radiation | — | UNRESOLVED |
| WBRT without avoidance of hippocampus | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- WBRT
- description
- Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
- interventionNames
- Radiation: WBRT without avoidance of hippocampus
- type
- EXPERIMENTAL
- label
- WBRT with avoidance of hippocampus
- description
- Patients with brain metastases (\>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
- interventionNames
- Radiation: WBRT with avoidance of hippocampus
- type
- EXPERIMENTAL
- label
- WBRT with TMZ
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Primary lesions diagnosed by pathology or cytology * Brain metastases confirmed by brain MRI or CT(\>3 brain metastases） * Brain metastases beyond 5mm of hippocampus * Male or female patients with age between 18 and 75 years old * Karnofsky Performance Scores ≥ 60 * Expected survival ≥ 6 months * No previous brain surgery or brain radiotherapy * Without dysfunction of heart, lung, liver, kidney and hematopoiesis * The primary carcinoma is under control Exclusion Criteria: * MMSE score \<27 * Dysfunction of heart, lung, liver, kidney or hematopoiesis * Severe neurological, mental or endocrine diseases * History of alcohol or drug abuse within 3 months * Visual or hearing dysfunction, low education level, or other reasons leading to not capable of taking the MMSE test * Currently under treatment may effect patients' neurocognitive functions * Patients participated in clinical trials of other drugs within last 3 months * Other unsuitable reason
References
Publications (0)
Data not yet available